Isomark, LLC

Non-Invasive Breath Monitoring Technology

Isomark’s patented non-invasive breath technology may allow for the early detection of infection. Isomark’s initial focus is the ICU ventilated patient.

Isomark’s technology is under development and not available for use.

LEARN MORE

Non-Invasive Breath Monitoring Technology

Real-Time Results

In addition to its non-invasive nature, Isomark’s technology could potentially provide near real-time results, in contrast to current diagnostic tests which require hours or days for laboratory analysis. This represents not only a significant health benefit to patients but also substantive cost savings to consumers, insurance companies, and healthcare providers. LEARN MORE

Making A Difference

Presently, 1.7 million hospital patients in the United States contract infections annually. Isomark’s technology could greatly improve the health outcomes of these patients while saving the hospital money.

Infection also represents one of the leading causes of premature birth and, by extension, birth defects. Because Isomark’s technology relies only on a breath sample, it also may have particular application and benefit in the detection of infection in newborns, for whom many diagnostic measures presently require blood samples. LEARN MORE

FDA Disclaimer

Caution – Investigational Device Limited by Federal Law to Investigational Use

FDA Timeline

Expected date to submit application to the FDA: March 2014

Early Infectious Disease Detection Technology

Isomark's patented breath technology may potentially offer a unique non-invasive method for rapid detection of invasive infections. Our goal is to assist healthcare providers to achieve a critical need for earlier and more accurate diagnostic techniques.

Do you want Isomark updates?

Sign up for our newsletter!